EZH2 and cancer: A series of HDMs inhibitors and HMT inhibitors involving LSD1 inhibitor SP-2577 (Seclidemstat) (NCT03895684), EZH2 inhibitor CPI-1205 (NCT03525795), Tazemetostat (NCT01897571) are in trials against multiple cancer types.